Palonosetron Morningside Healthcare

Palonosetron, the active ingredient in Palonosetron Morningside Healthcare, is a 5‑HT3 receptor antagonist presented as a 0.075 mg/1 ml solution for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and postoperative recovery in adult patients. GNH USA supplies Palonosetron Morningside Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Palonosetron is a selective 5‑HT3 receptor antagonist indicated for several nausea and vomiting pathways. - Chemotherapy‑induced nausea and vomiting (CINV): Provides long‑lasting protection against acute and delayed phases. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after surgery. - Radiotherapy‑induced nausea and vomiting: Helps control nausea associated with radiation treatment. - Anticipatory nausea and vomiting: Prevents nausea that occurs before chemotherapy in patients with prior experience. - Nausea related to other emetogenic triggers : Offers broader anti‑emetic coverage in clinical practice.

Palonosetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: transient gastrointestinal slowing. - Fatigue: occasional tiredness. - Dizziness: brief episodes of light‑headedness. - Injection site erythema: mild redness at the IV site.

Serious or Rare Side Effects: - Allergic reaction: rash, pruritus, or anaphylaxis. - Cardiac arrhythmia: QT‑interval prolongation. - Severe constipation or intestinal obstruction. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hypotension: notable drop in blood pressure post‑administration.

When using Palonosetron, clinicians should consider several safety aspects. - Assess cardiac history: patients with known QT prolongation require ECG monitoring. - Review concomitant serotonergic drugs: avoid additive serotonin effects. - Evaluate renal and hepatic function: dose adjustment may be needed in severe impairment. - Monitor for allergic reactions: watch for signs of rash or anaphylaxis during infusion. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Palonosetron may interact with other medications that influence serotonin pathways or cardiac conduction.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: concurrent use can increase toxicity risk. - QT‑prolonging agents (e.g., quinidine, sotalol): may exacerbate cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely): - Serotonergic antidepressants (SSRIs, SNRIs, MAOIs): potential for serotonin syndrome. - Antifungal azoles (ketoconazole, itraconazole): may affect drug metabolism. - CYP3A4 inhibitors/inducers: monitor plasma levels for altered exposure.